BioSpace News Archive

Cytovance® Biologics, a leading biopharmaceutical contract development and manufacturing organization of mammalian, microbial and gene therapy biologics, announces the next webinar of its 2021 series: pDNA Manufacturing: An Optimized Platform Process.

Masimo announced the findings of a study published in the Turkish Journal of Medical Sciences in which Dr. Ayten Saracoglu and colleagues at the Marmara University Pendik Training and Research Hospital in Istanbul evaluated the ability of ORi to guide oxygenation by measuring its impact on hyperoxemia-mediated morbidity during one-lung ventilation conducted as part of thoracic surgery.

Vibrating mesh nebulizers of various types have gained popularity in adult and pediatric patient populations as an advanced aerosol delivery device for respiratory therapy.

Hummingbird Bioscience announced that its Chief Scientific Officer and co-founder, Dr Jerome Boyd-Kirkup, will be speaking at the 2021 virtual symposium “VISTA: A New Immune Checkpoint in Cancer, Autoimmunity and Beyond”, taking place on June 18, 2021.

Isofol Medical AB fully guaranteed new share issue with preferential rights for the Company’s existing shareholders, which ended on June 10, 2021, was oversubscribed.

taiba Middle East announces that Insmed Netherlands BV, a subsidiary of Insmed Incorporated, a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, has granted taiba exclusive rights to market and distribute ARIKAYCE® in the Countries of Gulf Cooperation Council.

On June 14, GENECAST, a specialist in liquid biopsy-based cancer diagnostics, announced that it will begin a clinical study for the early diagnosis of non-small cell lung cancer.

EyeGate Pharmaceuticals, Inc. announced the first patient dosed in phase II proof-of-concept study evaluating its lead product candidate, PP-001, in patients with ocular surface inflammation due to ocular surface diseases including dry eye.

Athira Pharma, Inc., a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration, announced the appointment of Rachel Lenington as Chief Technology Officer, Head of Product Development Strategy, effective June 14.

Opthea Limited, a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, is pleased to announce the appointment of Mrs. Karen Adams as Vice President of Finance and Company Secretary, effective June 12, 2021.